All In Biotech

Drug Trial Radar · NCT06838676

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

A Phase II Trial of ACT001 in Children and Adolescents With Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 10, 2025

Primary completion

Jul 2028

Study completion Jul 2035

Sponsor

Lead sponsor
Nationwide Children's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Accendatech USA Inc.
First posted
Feb 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.

Conditions

  • Diffuse Intrinsic Pontine Gliomas (DIPG)
  • Progressive DIPG
  • Refractory DIPG
  • Recurrent DIPG
  • H3K27-altered High Grade Glioma

Interventions

  • ACT001Drug

    PO BID at 875 mg/m2 for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) for newly diagnosed DIPGTime frame: From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months
  2. Objective Response Rate (ORR) in Progressive/Refractory/Recurrent HGG after frontline RTTime frame: Date on treatment through 30 days following end of protocol treatment

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Not yet recruiting

  • Emory University/Children's Healthcare of Atlanta

    Atlanta, Georgia · Not yet recruiting

  • C.S. Mott Children's Hospital

    Ann Arbor, Michigan · Recruiting

  • St. Louis Children's Hospital

    St Louis, Missouri · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Not yet recruiting

  • Cincinnati Children's Hospital

    Cincinnati, Ohio · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Recruiting

  • Children's Hospital of Philidelphia

    Philidelphia, Pennsylvania · Not yet recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia · Recruiting

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia · Not yet recruiting

  • Royal Children's Hospital

    Melbourne, Victoria, Australia · Not yet recruiting

  • Perth Children's Hospital

    Perth, Western Australia, Australia · Not yet recruiting

  • The Hospital for Sick Children (SickKids)

    Toronto, Ontario, Canada · Recruiting

  • Montreal Children's Hospital

    Montreal, Quebec, Canada · Not yet recruiting

  • Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)

    Heidelberg, Baden-Wurttemberg, Germany · Not yet recruiting

  • Starship Children's Hospital

    Auckland, Grafton, New Zealand · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.